Brown JR et al. Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia: Interim analysis of the multicenter, open-label, randomized, phase 3 AMPLIFY trial. ASH 2024;Abstract 1009.

Coombs CC et al. Real-world treatment effectiveness in high-risk patients with chronic lymphocytic leukemia (CLL) receiving venetoclax-based therapy: An international study. EHA 2024;Abstract P665.

Ghosh N et al. Real-world treatment effectiveness in patients with chronic lymphocytic leukemia (CLL) receiving venetoclax-based therapy after Bruton tyrosine kinase inhibitors: An international study. EHA 2024;Abstract P671.

Jurczak W et al. Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies. EHA 2024;Abstract P618.

Kater AP et al. Epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia: Results from the phase 1b/2 EPCORE CLL-1 trial expansion cohort. iwCLL 2023;Abstract 1546171.

Lamanna N et al. Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy. eJHaem 2024;5(5):929-39. Abstract

Lamanna N et al. Treatment outcomes of patients treated with venetoclax-obinutuzumab therapy vs Btki therapies in 1L CLL: An international real-world study. ASH 2024;Abstract 4625.

Ma S et al. Combination of zanubrutinib + venetoclax for treatment naïve CLL/SLL with del(17p) and/or TP53: Preliminary results from SEQUOIA Arm D. EHA 2024;Abstract S160.

Mato AR et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med 2023;389(1):33-44. Abstract

Rhodes JM et al. Racial disparities in real-world treatment patterns and outcomes among patients with CLL. EHA 2023;Abstract P647.

Shadman M et al. Treatment discontinuation patterns for patients with chronic lymphocytic leukemia in real-world settings: Results from a multi-center international study. Clin Lymphoma Myeloma Leuk 2023;23(7):515-26. Abstract

Shah NN et al. Safety and tolerability of pirtobrutinib monotherapy in patients with B-cell malignancies who were previously intolerant to a covalent BTK inhibitor: Results from the phase 1/2 BRUIN Study. ASH 2022;Abstract 1797.

Thompson MC et al. Outcomes of therapies following discontinuation of non-covalent Bruton’s tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia and Richter transformation: Results from an international, multicenter study. ASH 2024;Abstract 1870.

Wierda WG et al. Pirtobrutinib, a highlight selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: Analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol 2024;11(9):e682-92. Abstract